Transcode Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$28.0M | -$15.7M | -$19.4M | -$18.6M | -$6.2M |
| Operating expenses | $28.0M | $15.7M | $19.4M | $18.6M | $6.2M |
| Cash from operations | -$19.5M | -$13.3M | -$18.1M | -$15.8M | -$5.3M |
| Capital expenditure | $6,660 | $21,761 | $35,609 | $100,919 | $254,820 |
| Free cash flow | -$19.5M | -$13.4M | -$18.1M | -$15.9M | -$5.5M |
| Impairments | $0 | — | — | — | — |
| Total assets | $162.4M | $7.3M | $5.2M | $7.6M | $22.9M |
| Total liabilities | $10.5M | $9.3M | $3.5M | $4.3M | $2.5M |
Shares outstanding 950.3K · Free float 81.0%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.